Skip to content
Screener

Ionis Pharmaceuticals IONS Liability Related To Sale Of Future Royalties Net Noncurrent

Liability Related To Sale Of Future Royalties Net Noncurrent at other companies

Geron logo
GeronGERN
$108.93M-1.4%
Geron logo
GeronGERN
$108.93M-1.4%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Geron logo
GeronGERN
$20.69M+18.6%
Geron logo
GeronGERN
$20.69M+18.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+43.9%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.06B+39.6%
Enterprise value$8.97B+28.4%
P/S10.4×+3.5×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:LiabilityRelatedToSaleOfFutureRoyaltiesNetNoncurrent.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemJune 30, 2026December 31, 2025
Long-term deferred contract revenue63,03092,001
0 percent convertible senior notes due 2030, net753,356751,495
1.75 percent convertible senior notes due 2028, net569,255567,830
Liability related to sale of future royalties, net562,574551,353
Long-term lease liabilities262,476262,383
Long-term obligations28,43528,118
Total liabilities2,554,7643,034,747
Stockholders’ equity:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent?
Ionis Pharmaceuticals (IONS) reported liability related to sale of future royalties net noncurrent of $562.57M in Q2 2026.
How has Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent changed year-over-year?
Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent increased by 3.9% year-over-year, from $541.21M to $562.57M.
What does liability related to sale of future royalties net noncurrent mean?
A non-current liability representing the obligation to pay future royalty streams to a third party in exchange for an upfront cash payment. This reflects a financing arrangement where the company monetizes future intellectual property cash flows to fund current operations.

Ask your AI about Ionis Pharmaceuticals's liability related to sale of future royalties net noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude